Abaloparatide Before Total Knee Arthroplasty
An Open-Label Phase 2 Study of Abaloparatide to Mitigate Distal Femoral Bone Loss Following Total Knee Arthroplasty
Sponsor: Radius Health, Inc.
A PHASE4 clinical study on Arthroplasties, Knee Replacement and Osteoporosis, this trial is completed. The trial is conducted by Radius Health, Inc. and has accumulated 14 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
May 2025 — Present [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Feb 2025 — May 2025 [monthly]
Active Not Recruiting PHASE4
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE4
-
Dec 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
▶ Show 9 earlier versions
-
Apr 2023 — Dec 2023 [monthly]
Recruiting PHASE4
-
May 2022 — Apr 2023 [monthly]
Recruiting PHASE4
-
Jun 2021 — May 2022 [monthly]
Recruiting PHASE4
-
Mar 2021 — Jun 2021 [monthly]
Recruiting PHASE4
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE4
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE4
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jan 2020 — Feb 2020 [monthly]
Not Yet Recruiting PHASE4
-
Dec 2019 — Jan 2020 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Radius Health, Inc.
- University of Wisconsin, Madison
For direct contact, visit the study record on ClinicalTrials.gov .